Arch Therapeutics Inc (ARTH)

[formerdtrader]

Don't disagree about the need to raise more money, but if the results are there and they can generate interest and momentum for the purchase of their stock, they wont need to dilute further. They can use treasury stock to fund additional business ventures.

Not to mention, positive trial results in the next 2-3 months should make them a very attractive acquisition or joint venture play.

either way, it is a sad state of affairs that companies that are really close in the biotech world have a complete different valuation model than "pie in the sky", "might be great one day" companies, whose stocks skyrocket on absolute nothing.